BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32808500)

  • 1. Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study.
    Falcone F; Leone Roberti Maggiore U; Di Donato V; Perrone AM; Frigerio L; Bifulco G; Polterauer S; Casadio P; Cormio G; Masciullo V; Malzoni M; Greggi S
    J Gynecol Oncol; 2020 Sep; 31(5):e74. PubMed ID: 32808500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.
    Falcone F; Laurelli G; Losito S; Di Napoli M; Granata V; Greggi S
    J Gynecol Oncol; 2017 Jan; 28(1):e2. PubMed ID: 27670256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update.
    Laurelli G; Falcone F; Gallo MS; Scala F; Losito S; Granata V; Cascella M; Greggi S
    Int J Gynecol Cancer; 2016 Nov; 26(9):1650-1657. PubMed ID: 27654262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women.
    Shan BE; Ren YL; Sun JM; Tu XY; Jiang ZX; Ju XZ; Zang RY; Wang HY
    Arch Gynecol Obstet; 2013 Nov; 288(5):1115-23. PubMed ID: 23644919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
    De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
    J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
    Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
    Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility sparing treatment in patients with endometrial cancer (FERT-ENC): a multicentric retrospective study from the Spanish Investigational Network Gynecologic Oncology Group (SPAIN-GOG).
    Lago V; Marina T; Laseca Modrego M; Gil-Ibañez B; Rodriguez JR; Domingo J; Minig L; Padilla-Iserte P; Arencibia Sánchez O; Sala Ferichola M; Munmanny M; Martín Salamanca B; Iacoponi S; Cabrera S; Coronado P; Utrilla-Layna J; Bataller Á; Fiol G; Corbalán S; Espinosa E; Gil-Moreno A; Domingo S;
    Arch Gynecol Obstet; 2022 Sep; 306(3):821-828. PubMed ID: 35122158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
    Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
    Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinoma.
    Ou YC; Fu HC; Lan J; Wu CH; Kung FT; Lan KC; Tsai YC; Lin H
    Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():99-104. PubMed ID: 34739876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.
    Herrera Cappelletti E; Humann J; Torrejón R; Gambadauro P
    Hum Reprod Update; 2022 Feb; 28(2):282-295. PubMed ID: 34935045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
    Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
    Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary.
    Gama Q; Luo S; Wu P; Wang L; Liu S; Zhang H; Sun L; Wang Y; Yu M; Chen X; Shan W; Luo X
    J Ovarian Res; 2023 Dec; 16(1):235. PubMed ID: 38062462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
    Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
    Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia.
    Xi Y; Liu G; Liu D; Jiang J; Gong R
    Arch Gynecol Obstet; 2023 Feb; 307(2):583-590. PubMed ID: 35674831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series.
    Falcone F; Normanno N; Losito NS; Scognamiglio G; Esposito Abate R; Chicchinelli N; Casella G; Laurelli G; Scaffa C; Greggi S
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():220-225. PubMed ID: 31326637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
    Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
    J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.